Our clinical development programs focus on treating solid tumors, sepsis
and COVID-19. Our most advanced product candidate, Allocetra™ was developed
for the reprogramming of diseased macrophages in patients with sepsis
or COVID-19, and has demonstrated positive safety, tolerability and efficacy
in several clinical trials. We plan on initiating clinical trials of Allocetra™
in solid cancer patients during 2021.